Global Leading Market Research Publisher QYResearch announces the release of its latest report “Preeclampsia Laboratory Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. For obstetricians, maternal-fetal medicine specialists, and healthcare system administrators, preeclampsia remains one of the most formidable challenges in pregnancy care—a hypertensive disorder that affects 2-8% of pregnancies worldwide and remains a leading cause of maternal and perinatal morbidity and mortality. Traditional diagnosis, relying on blood pressure measurement and proteinuria assessment, has proven inadequate for early identification of women at risk, often detecting the condition only after it has progressed to a dangerous stage. Preeclampsia laboratory testing addresses this critical gap by providing objective, quantitative biomarkers that enable early detection, risk stratification, and timely intervention—transforming preeclampsia management from reactive crisis response to proactive risk management. This report delivers a comprehensive strategic assessment of a market poised for strong growth, quantifying the value proposition that is driving adoption across hospitals, diagnostic laboratories, and women’s health practices as the understanding of preeclampsia pathophysiology translates into clinically actionable diagnostic tools.
Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Preeclampsia Laboratory Testing market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Preeclampsia Laboratory Testing was estimated to be worth US$ 507 million in 2024 and is forecast to a readjusted size of US$ 773 million by 2031 with a CAGR of 6.3% during the forecast period 2025-2031.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/3670853/preeclampsia-laboratory-testing
Market Trajectory: Strong Growth Anchored in Clinical Adoption and Guideline Integration
The projected 6.3% CAGR reflects a market benefiting from the translation of decades of preeclampsia research into clinically validated diagnostic tools. According to recent data from the World Health Organization (WHO) and the International Society for the Study of Hypertension in Pregnancy (ISSHP), preeclampsia contributes to approximately 70,000 maternal deaths and 500,000 fetal and neonatal deaths annually worldwide, creating urgent demand for improved diagnostic and predictive capabilities.
Several factors are driving market expansion. The integration of preeclampsia biomarkers into clinical practice guidelines—including the American College of Obstetricians and Gynecologists (ACOG) and the International Federation of Gynecology and Obstetrics (FIGO) recommendations—has created a formal framework for laboratory testing adoption. The increasing recognition that preeclampsia is not a single disease but a syndrome with multiple pathophysiological pathways has driven development of multi-marker panels that provide more accurate risk assessment than single-biomarker approaches. Additionally, the growth of personalized and preventive obstetrics has created demand for tools that enable early identification of at-risk women who may benefit from aspirin prophylaxis, intensified monitoring, or timely delivery.
Technology Segmentation: Blood Tests and Urine Tests
The market’s segmentation by test type—Blood Tests and Urine Tests—reveals complementary diagnostic approaches with distinct clinical applications.
Blood Tests represent the largest and fastest-growing segment, encompassing measurement of circulating angiogenic factors—specifically soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF). The ratio of sFlt-1 to PlGF has emerged as the most validated biomarker panel for preeclampsia diagnosis and prognosis. A landmark clinical trial demonstrated that a sFlt-1/PlGF ratio below 38 has a negative predictive value exceeding 99% for ruling out preeclampsia in the subsequent week—a finding that has transformed clinical practice by enabling clinicians to confidently discharge women with suspected preeclampsia who are at low risk of progression.
A case study from a large European maternity hospital illustrates the impact of angiogenic factor testing: implementation of sFlt-1/PlGF testing for women presenting with suspected preeclampsia reduced hospital admissions by 35%, reduced maternal transfers to tertiary care centers by 40%, and shortened average length of stay for confirmed preeclampsia cases by 2.5 days—translating to substantial healthcare cost savings while improving patient experience.
Urine Tests encompass traditional proteinuria assessment—the historic standard for preeclampsia diagnosis—as well as emerging biomarkers including urinary proteomics and metabolomic panels. While urine protein measurement remains widely used due to its low cost and familiarity, it has limitations including variability, poor correlation with disease severity, and inability to distinguish preeclampsia from other hypertensive disorders.
Application Segmentation: Hospitals and Clinics, Diagnostics Centers
The hospitals and clinics segment represents the dominant market for preeclampsia laboratory testing, encompassing labor and delivery units, maternal-fetal medicine practices, and emergency departments where women with suspected preeclampsia present. Hospital-based testing enables rapid turnaround for clinical decision-making, with point-of-care and near-patient testing platforms emerging to accelerate result availability. A case study from a US tertiary care center illustrates the value of rapid turnaround: implementation of same-day sFlt-1/PlGF testing reduced the time from presentation to diagnosis from 24-48 hours to under 4 hours, enabling earlier initiation of appropriate management and reducing unnecessary admissions.
The diagnostics centers segment includes reference laboratories and specialized women’s health testing facilities. These centers serve both high-risk obstetric practices that pre-order testing for risk assessment and centralized testing for healthcare systems where hospital-based testing is not available. The diagnostics center segment has grown as awareness of preeclampsia biomarkers has expanded beyond tertiary care centers to community hospitals and outpatient practices.
Competitive Landscape: Diagnostic Leaders and Specialized Women’s Health Innovators
The preeclampsia laboratory testing market features a mix of global diagnostic leaders and specialized women’s health companies.
F. Hoffmann-La Roche Ltd. , ThermoFischer Scientific Inc. , Siemens Healthineers AG , Bayer AG , and PerkinElmer Inc. represent the global diagnostic leaders, offering preeclampsia testing platforms integrated with their broader immunoassay and molecular diagnostic portfolios. These companies benefit from established distribution networks, regulatory expertise, and relationships with hospital laboratories.
SERA Prognostics , Metabolomic Diagnostics Ltd. , DiabetOmics Inc. , DRG INSTRUMENTS GMBH , and Progenity Inc. represent specialized women’s health companies, with focused product development in preeclampsia and other obstetric conditions. These companies have driven innovation in multi-marker panels and predictive algorithms that extend beyond the sFlt-1/PlGF ratio.
Exclusive Industry Insight: The Shift from Diagnosis to Prediction
The defining trend shaping the preeclampsia laboratory testing market is the evolution from diagnostic testing—confirming preeclampsia in symptomatic women—to predictive testing—identifying women at risk before clinical symptoms develop. First-trimester screening algorithms that combine maternal characteristics, biophysical markers, and angiogenic factor levels can identify women at elevated risk for preterm preeclampsia with detection rates exceeding 80% at a 10% false-positive rate.
For strategic decision-makers, the preeclampsia laboratory testing market presents a compelling opportunity characterized by strong growth driven by clinical adoption, guideline integration, and the shift from diagnostic to predictive testing. The projected expansion from US$ 507 million to US$ 773 million by 2031 reflects a market where biomarker validation, clinical utility evidence, and integration into routine obstetric care will define competitive success.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
